A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771
Via Sette Santi, 1 50131 - Firenze (Firenze) Telefono +39 055 56801 Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People. Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
2021 - 1 - 22
We at Menarini are committed in making a difference in lives of patients. 23rd January 2021 marks the second annual BPDCN Awareness Day (#BPDCNday) since it received its own classification as a distinct hematologic malignancy by the World Health Organization (WHO). We encourage everyone to join the community in raising awareness to bring patients and health care professionals together in the fight against a deadly disease that has largely gone under-recognized.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematological malignancy with estimated 0.44% of hematologic neoplasms annually – equivalent to roughly 700 cases in the United States and 1000 cases in Europe.1 Its outcomes are poor and it has largely gone under-recognized.2 Despite an initial response, BPDCN remains aggressive and associated with a dismal prognosis.2-4 Historically, the average overall survival rate after diagnosis is 8-14 months.3,5.
BPDCN is a disease that is mostly diagnosed in elderly patients, but it can occur at any age.2,6 Men are three times more likely to be affected by BPDCN than women.2,6 A strong similarity with other malignancies further contributes to frequent misdiagnosis.7,9
Given that the disease presents variable dermatologic and hematologic manifestations, biopsies of skin, bone marrow or secondary sites are critical for diagnosis.2,7,10-14 Tumor cells are characterized by the expression of CD123, CD4, CD56*2,3,15, providing a suitable marker triad that can confirm the diagnosis of BPDCN.3,7 An early and correct diagnosis of BPDCN may be key in addressing the dismal prognosis and poor outcomes of patients.
Consequently, diagnosis of BPDCN is a multidisciplinary responsibility, involving dermatologists, hemato-oncologists and pathologists. A joint effort could help avert misdiagnosis and enable an early and correct initiation of treatment.
Although BPDCN is under-recognized, enhancing knowledge may help define the disease and improve diagnosis and outcome. Opportunities such as #BPDCNDay provide an opening to engage the community to raise awareness and bring patients and health care professionals together in the fight against this challenging disease.
We hope you will join us in supporting patients and families affected by BPDCN around the world.
For more information, visit BPDCNinfo.com
* as well as other markers (TCL1, TCF4, and CD303 (BDCA2)
1. Sullivan JM, Rizzieri DA. Hematology Am Soc Hematol Educ Program. 2016;2(1):16-23.; 2. Facchetti et al. Mod Pathol. 2016;29(2):98-111.; 3. Pagano et al. Haematologica. 2013;98(2):239-246.; 4. Menezes et al. Leukemia. 2014;28(4):823-829.; 5. Pemmaraju N. Curr Hematol Malig Rep. 2017;12(6):510–512.; 6. Sapienza et al. Haematologica. 2019;104(4):729-737.; 7. Pagano et al. Br J Haematol. 2016;174(2):188-202.; 8. Laribi et al. Biol Blood Marrow Transplant. 2016;22(8):1357-1367.; 9. Riaz et al. Cancer Control. 2014;21(4):279-289.; 10. León-Martínez et al. Int J Surg Pathol. 2014;22(1):76-82.; 11. Julia et al. Br J Dermatol. 2013;169(3):579-586.; 12. Herling&Jones. Am J Clin Pathol. 2007;127(5):687-700.M; 13. Reichard. Surg Pathol Clin. 2013;6(4):743-765.; 14. Frankel et al. Blood. 2014;124(3):385-392.; 15. Ceribelli et al. Cancer Cell, 2016;30(5):764–778.
Discover our stories from all over the world
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.
Scopri le nostre storie da tutto il mondo